Back to search

Article

Cancer cell-selective ecotopic expression of CD20 as an antigen enables rituximab repurposing for solid tumor immunotherapy

2025-10-16

Abstract excerpt

Despite the clinical success of cancer immunotherapies, their efficacy is often compromised by antigen-related problems, including heterogeneity, downregulation, loss, and off-tumor toxicity. To overcome these limitations that challenge the current immunotherapies dependent on native antigens, we here describe a new cancer immunotherapy strategy, which artificially and specifically expresses a clinical validated a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4d5027dd-98a0-5b14-b3cc-1754813832ea
DOI
10.1101/2025.10.16.682764
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Cancer cell-selective ecotopic expression of CD20 as an antigen enables rituximab repurposing for solid tumor immunotherapyDOI 10.1101/2025.10.16.682764
Cancer immunotherapy for metastasis: past, present and futureSemantic proximity
Cancer Vaccines: Antigen Selection StrategySemantic proximity
Criteria to make animal studies more relevant to treating human cancer.Semantic proximity
Nanobody-based therapeutics against colorectal cancer: Precision therapies based on the personal mutanome profile and tumor neoantigens.Semantic proximity
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.Semantic proximity
A CHIMERIC RECEPTOR ENABLING ANTIBODY-GUIDED RETARGETING OF CAR T- CELLSSemantic proximity
The arming of NK cells with Fc-engineered rituximab confers them specificity against CD20-expressing cellsSemantic proximity
AI-Guided CAR Designs and AKT3 Degradation Synergize to Enhance Bispecific and Trispecific CAR-T Cell Persistence and Overcome Antigen EscapeSemantic proximity
In vivo expression of anti-CD19/CD3 BiTE by liver-targeted AAV for the treatment of B cell malignanciesSemantic proximity
A computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of actionSemantic proximity
The Application of Nanobody in CAR-T TherapySemantic proximity
Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review)Semantic proximity
Select a neighboring publication to make it the new centre.